Leukapheresis Market worth $91 million by 2026 - Exclusive Report by MarketsandMarkets Leukapheresis Market by Product (Devices, Filters, Columns, Disposables), Leukopak (Mobilized, Non-Mobilized), Indication (ALL, NHL, Multiple Myeloma), Application (Research, Therapeutic), End User (Hospitals, Pharma, Biotech) - Global Forecast to 2026 , published by MarketsandMarkets, the global Leukapheresis Market is projected to reach USD 91 million by 2026 from USD 61 million in 2021, at a CAGR of 8.4% during the forecast period. The leukopaks market is expected to reach USD 662 million by 2026, at a CAGR of 41.9%.
Browse in-depth TOC on
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=20283148
The Leukopaks are enriched leukapheresis products that contain higher concentrations of leukocytes. The increasing incidence and prevalence of leukemia and growing demand for leukopaks for research applications are some of the factors driving the growth of these mar
Pfizer s New Oral Protease Inhibitor Could Possibly Treat And Prevent Covid-19
forbes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forbes.com Daily Mail and Mail on Sunday newspapers.
Lexaria Expands COVID-19 Drug Research Program Utilizing Proprietary DehydraTECH - Press Release
digitaljournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from digitaljournal.com Daily Mail and Mail on Sunday newspapers.
Lexaria Expands COVID-19 Drug Research Program Utilizing Proprietary DehydraTECH
albuquerqueexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from albuquerqueexpress.com Daily Mail and Mail on Sunday newspapers.
Lexaria Bioscience Corp.: Lexaria Expands COVID-19 Drug Research Program Utilizing Proprietary DehydraTECH
Remdesivir is one of several drugs to be evaluated
KELOWNA, BC / ACCESSWIRE / December 22, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the Company or Lexaria ), a global innovator in drug delivery platforms, today announced that it has initiated the next phase of its antiviral drug research program following successful results from a recent animal study announced on December 1, 2020.
The recent animal study demonstrated that DehydraTECH
TM technology significantly improved drug delivery in animals of representative drugs from two classes of antiviral therapies (a Protease Inhibitor and a Reverse Transcriptase Inhibitor)